Lodi, Sara; del Amo, Julia; d'Arminio Monforte, Antonella; Abgrall, Sophie; Sabin, Caroline; Morrison, Charles; Furrer, Hansjakob; Muga, Roberto; Porter, Kholoud; Girardi, Enrico (2013). Risk of tuberculosis following HIV seroconversion in high-income countries. Thorax, 68(3), pp. 207-213. BMJ Publishing Group 10.1136/thoraxjnl-2012-201740
Text
207.full.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (192kB) |
Background Few data exist on tuberculosis (TB) incidence according to time from HIV seroconversion in high-income countries and whether rates following initiation of a combination of antiretroviral treatments (cARTs) differ from those soon after seroconversion.
Methods Data on individuals with well estimated dates of HIV seroconversion were used to analyse post-seroconversion TB rates, ending at the earliest of 1 January 1997, death or last clinic visit. TB rates were also estimated following cART initiation, ending at the earliest of death or last clinic visit. Poisson models were used to examine the effect of current and past level of immunosuppression on TB risk after cART initiation.
Results Of 19 815 individuals at risk during 1982–1996, TB incidence increased from 5.89/1000 person-years (PY) (95% CI 3.77 to 8.76) in the first year after seroconversion to 10.56 (4.83 to 20.04, p=0.01) at 10 years. Among 11 178 TB-free individuals initiating cART, the TB rate in the first year after cART initiation was 4.23/1000 PY (3.07 to 5.71) and dropped thereafter, remaining constant from year 2 onwards averaging at 1.64/1000 PY (1.29 to 2.05). Current CD4 count was inversely associated with TB rates, while nadir CD4 count was not associated with TB rates after adjustment for current CD4 count, HIV-RNA at cART initiation.
Conclusions TB risk increases with duration of HIV infection in the absence of cART. Following cART initiation, TB incidence rates were lower than levels immediately following seroconversion. Implementation of current recommendations to prevent TB in early HIV infection could be beneficial.
Item Type: |
Journal Article (Original Article) |
---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology |
UniBE Contributor: |
Furrer, Hansjakob |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0040-6376 |
Publisher: |
BMJ Publishing Group |
Language: |
English |
Submitter: |
Annelies Luginbühl |
Date Deposited: |
21 Mar 2014 10:58 |
Last Modified: |
05 Dec 2022 14:29 |
Publisher DOI: |
10.1136/thoraxjnl-2012-201740 |
BORIS DOI: |
10.7892/boris.44328 |
URI: |
https://boris.unibe.ch/id/eprint/44328 |